

### **HEALTHCARE MONTHLY**

SEPTEMBER 2019

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma **Healthcare Services**  Life Sciences / Diagnostics

**Medical Devices** 

#### **HEADLINE TRANSACTIONS**

ACOUROR

ACQUISITION SYNOPSIS







- Amgen Inc. (NasdagGS:AMGN) entered into a definitive agreement to acquire the worldwide rights to Otezla from Celgene Corporation (NasdagGS:CELG) for \$13.4 billion
- Otezla is a leading treatment for plague psoriasis and psoriatic arthritis with potential for treating other immune system related inflammatory diseases
- · Amgen Inc. is an American multinational biopharmaceutical company, specializing in the development of human therapeutics





- · Elanco Animal Health Inc. (NYSE:ELAN) entered into a share and asset purchase agreement to acquire Bayer Animal Health for \$7.6 billion
- · Bayer Animal Health engages in the research and development of products for animal health and pest control
- · Elanco Animal Health Inc. develops products for companion and food animals





- Permira Advisors LLC entered into a definitive agreement to acquire Cambrex Corporation (NYSE:CBM) for \$2.1 billion, a 47.1% premium
- · Cambrex Corporation provides various products and services for the development of new and generic therapeutics worldwide
- · Permira Advisors LLC is a UK based private equity firm operating internationally
- Implied Enterprise Value Multiples: 4.6x Revenue, 17.9x EBITDA





- · Siemens Healthineers AG signed a definitive agreement to acquire Corindus Vascular Robotics, Inc. (AMEX:CVRS) for \$1.1 billion, a 76.9%
- · Corindus Vascular Robotics, Inc. manufactures robotic-assisted systems for use in interventional vascular procedures
- Siemens Healthineers AG provides healthcare information technology products
- Implied Enterprise Value Multiples: 71.3x Revenue






BioTech / Pharma




# **HEALTHCARE GROWTH &**

## **VALUATION TRENDS**


#### **Enterprise Value / LTM Revenue**




#### **Enterprise Value / LTM EBITDA**



#### LTM Revenue Growth




#### LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

#### LTM Stock Price Index





# SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transaction
BlueRock Therapeutics LP	Bayer Aktiengesellschaft	BlueRock Therapeutics LP develops engineered cell therapies in the fields of neurology Transaction Value: \$240 million and up to \$360 million in milestones
Modis Therapeutics, Inc.	Zogenix, Inc.	Modis Therapeutics, Inc. develops disease modifying therapies for rare genetic diseases Transaction Value: \$250 million and up to \$150 million in milestones
Cavion LLC	Jazz Pharmaceuticals plc	Cavion LLC develops therapies to restore the brain's natural rhythms by modulating overactive T-type calcium channels Transaction Value: \$52.5 million and up to \$260 million in milestones

Target	Acquiror	Health Services Transaction
WebPT, Inc.	Warburg Pincus LLC	WebPT, Inc. develops electronic medical record and practice management solutions for physical therapists, occupational therapists and speech-language pathologists in the United States
ProKnow, LLC.	Elekta AB	ProKnow, LLC. designs and develops cloud-based software solutions to improve quality in radiation oncology worldwide
QxMD Software Inc.	WebMD Health Corp.	QxMD Software Inc. develops apps for healthcare professionals

Target	Acquiror	Life Sci / Diagnostics Transaction
XynManagement, Inc.	CareDx, Inc	XynManagement, Inc. develops software for transplant quality tracking and Scientific Registry of Transplant Recipients (SRTR) reporting
Taxon Biosciences, Inc.	Lavie Bio Ltd.	Taxon Biosciences, Inc. develops microbiome-based transformative applications for the agriculture, life sciences and oil and gas industries
cytena GmbH	Cellink AB (publ)	cytena GmbH develops a laboratory device to separate single cells

Target	Acquiror	Medical Devices Transaction
Avedro, Inc.	Glaukos Corporation	Avedro, Inc. develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness Transaction Value: \$486 million
SentreHEART, Inc.	AtriCure, Inc.	SentreHEART, Inc. manufactures devices for remote delivery of sutures for closure of anatomic structures Transaction Value: \$40 million and up to \$260 million in milestones
Collagen Matrix, Inc.	Linden LLC	Collagen Matrix, Inc. designs medical equipment and collagen for tissue and organ repair

#### **Selected TM Capital Healthcare Experience**







#### TM Capital's Healthcare Industry Contacts



James McLaren, Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman, Managing Director mgoldman@tmcapital.com 212.809.1419



Paul Smolevitz, Managing Director psmolevitz@tmcapital.com 212.809.1416

